RECRUITINGOBSERVATIONAL
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
About This Trial
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Who May Be Eligible (Plain English)
Who May Qualify:
1. Participants with confirmed Sickle Cell Disease.
2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
3. Willing and able to provide willing to sign a consent form
4. Ability to comply with study related evaluations and follow-up visits.
Who Should NOT Join This Trial:
1\. Known primary weakened immune system syndrome, cancer, or acquired weakened immune system syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Participants with confirmed Sickle Cell Disease.
2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
3. Willing and able to provide informed consent
4. Ability to comply with study related evaluations and follow-up visits.
Exclusion Criteria:
1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Locations (3)
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Korle Bu Teaching Hospital
Accra, Ghana, Ghana
Bugando Medical Centre
Mwanza, Tanzania